(Q37787119)

23 August 2017

Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer (English)

1 reference

23 August 2017

0 references

1 reference

5

Yair Lotan

1 reference

23 August 2017

Ganesh V Raj

1

1 reference

23 August 2017

Saumil Karavadia

2

1 reference

23 August 2017

Bruce Schlomer

3

1 reference

23 August 2017

Yull Arriaga

4

1 reference

23 August 2017

Arthur Sagalowsky

6

1 reference

23 August 2017

Eugene Frenkel

7

1 reference

23 August 2017

language of work or name

English

0 references

publication date

9 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

117

1 reference

23 August 2017

2

1 reference

23 August 2017

276-282

1 reference

Bladder cancer: epidemiology, staging and grading, and diagnosis.

23 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Adjuvant chemotherapy of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Defining optimal therapy for muscle invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Gemcitabine and cisplatin for advanced, metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Selection of patients may limit the generalizability of results from cancer trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25429

7 January 2021

Identifiers

DOI

10.1002/CNCR.25429

1 reference

23 August 2017

1 reference